SCNI

• Strategic Transformation: Scinai has materially transformed from a pure-play R&D company into a dual-platform entity combining innovative immunology R&D with a broader two-site CDMO business (Jerusalem and Yavne, Israel) following the acquisition of former Recipharm operations.
• Operational Focus Shift: Management’s focus has shifted from integration to execution, commercialization, and increasing infrastructure utilization across both sites.
• Capability Expansion: The Jerusalem site focuses on biologics development, analytical services, aseptic processing, and clinical CGMP manufacturing. The Yavne site adds early chemistry development and small-scale CGMP manufacturing for APIs.
• Customer Traction: As of August 16, 2026, committed customer orders totaled approximately $3.1 million, distributed almost equally between Jerusalem ($1.5 million) and Yavne ($1.6 million). Approximately $2.1 million had been invoiced by August 10.
• U.S. Clinical Engagement: A key U.S. client relationship has expanded from feasibility studies to broader CMC development and clinical manufacturing for FDA submission support, with approximately $650,000 in cash received post-quarter-end.
• R&D Discipline: The company is prioritizing capital discipline in its R&D pipeline, specifically regarding the NanoAb platform and PC111 program (under option agreement with Pincell), seeking non-dilutive funding and partnerships rather than internal financing for all stages.

• Maintains the objective of achieving approximately $5 million in CDMO revenue for fiscal year 2026.
• Success criteria include converting customer work into recognized revenue, expanding authorized work across sites, increasing infrastructure utilization, and generating repeat business.
• No specific forward-looking financial metrics (e.g., EBITDA, net income) were provided beyond the maintained $5 million revenue target.

The company operates two primary segments: Immunology R&D and CDMO (Contract Development and Manufacturing Organization). For the first half of 2026, total revenue was approximately $949,000, an increase from $773,000 in the same period of 2025. The expanded CDMO footprint resulted in a gross loss of approximately $2.37 million and an operating loss of approximately $4.6 million due to higher fixed costs before full utilization ramp-up. A non-cash bargain purchase gain of approximately $6.4 million from the Recipharm acquisition led to a reported net income of approximately $1.57 million. Specific revenue breakdowns by segment or percentage contributions were not disclosed.

• Operating Losses: The underlying business continues to generate operating losses ($4.6 million in H1 2026) as revenues scale against a larger fixed cost base.
• Liquidity Constraints: Cash and restricted cash stood at approximately $2.85 million as of June 30, 2026, necessitating additional capital.
• Revenue Recognition Timing: Committed orders do not guarantee immediate revenue; recognition depends on project execution and accounting criteria satisfaction.
• Dilution Risk: While management emphasizes disciplined capital allocation, any future equity issuance via the SEPA or other means will be dilutive.

Q: Does the update to the F-1 registration statement for the $15 million SEPA indicate an imminent $15 million dilution? / A: No, the update is a routine post-effective amendment reflecting June 30 financials and an ADS ratio change, not a new financing decision. Management retains sole discretion over when and how much to draw from the SEPA facility. Advances are priced at 97% of VWAP without warrants, and the company views this as a flexible tool alongside operational cash flow and non-dilutive grants rather than an automatic funding source.

Q: Given the $2.85 million cash balance, what is the strategy for securing additional capital? / A: The strategy combines operational execution with disciplined financing. Priorities include expanding the customer base, structuring agreements with advances/milestones to improve cash flow, and controlling discretionary spending. Financing efforts focus on non-dilutive sources like government grants and selective use of the SEPA, avoiding reliance on a single capital source.

Q: How should investors interpret the $3.1 million in committed customer orders relative to the $5 million revenue target? / A: Committed orders are a management KPI representing signed purchase orders, not a direct forecast of future revenue or cash. Of the $3.1 million, $2.1 million was already invoiced by mid-August, while $1 million remained un-invoiced. Revenue recognition depends on service completion and accounting rules, so these figures should not be mechanically added to the $5 million annual target but serve as indicators of commercial progress.